Cevostamab is a bispecific T-cell engager antibody that targets both FCRH5 found on cancer cells and CD3 antigen found on T lymphocytes.
| SparkCures ID | 290 |
|---|---|
| Developed By | Genentech |
| Generic Name | Cevostamab |
| Additional Names | BFCR4350A |
| Treatment Classifications | |
| Treatment Targets |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
September 23, 2025
On Monday Roche highlighted data from the phase 1 Camma 1 trial of the same combo in the second-line plus setting. Among 54 patients, the overall response rate was 86% and 88% with cevostamab at 70mg and 105mg respectively. Roche added that the grade 3 infection rate was less than 30%; the company is currently finalising the choice of dose for phase 3.
There are no resources, links or videos to display for this treatment.